Filing Details
- Accession Number:
- 0001104659-21-032850
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-05 17:45:39
- Reporting Period:
- 2021-03-04
- Accepted Time:
- 2021-03-05 17:45:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1279704 | Cellectar Biosciences Inc. | CLRB | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1202770 | V James Caruso | C/O Cellectar Biosciences, Inc., 100 Campus Drive Florham Park NJ 07932 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-03-04 | 5,100 | $1.70 | 86,401 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Acquisiton | 2021-03-04 | 1,600,000 | $0.00 | 1,600,000 | $1.74 |
Common Stock | Series A Warrants | Acquisiton | 2021-03-04 | 46,948 | $0.19 | 4,694 | $30.40 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,600,000 | 2031-03-04 | No | 4 | A | Direct | |
0 | 2016-04-20 | 2021-04-20 | No | 4 | S | Direct |
Footnotes
- Mr. Caruso used the proceeds of the sale of the Series A Warrants, which expire in April 2021, to purchase shares of Cellectar's common stock.
- Ten warrants are convertible into one share of Cellectar's common stock at an exercise price of $30.40 per share of common stock.
- This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.